Nuvasive Inc (NUVA) 66.74 $NUVA Zimmer Biomet's
Post# of 273257
Posted On: 09/04/2016 7:13:46 AM
Nuvasive Inc (NUVA) 66.74 $NUVA
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Bet on These 5 Profitable Stocks for Big Returns
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 6:26AM CDT
A company with strong profit generating capabilities usually has the proficiency to meet business expenses and create steady returns for investors.
FB: 126.51 (+0.34), TPH: 13.44 (+0.07), PE: 34.86 (+0.57), CORT: 5.31 (-0.04), NUVA: 66.74 (+0.68)
NuVasive to Participate in Investor Events in September 2016
Marketwired - Fri Sep 02, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - September 02, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will participate in the following investor events in September 2016:
WFC: 50.55 (+0.12), NUVA: 66.74 (+0.68)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 40.64 (+0.93), BDX: 177.32 (+0.30), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
Inogen Hits 52-Week High on Solid Q2 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:01AM CDT
Share price of Inogen Inc (INGN) rallied to a new 52-week high of $59 on Aug 30, eventually closing a tad bit lower at $58.46.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), NUVA: 66.74 (+0.68)
Veeva Systems (VEEV) Q2 Earnings, Revenues Top; View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:57AM CDT
Veeva Systems (VEEV) reported adjusted earnings of 15 cents per share in the second-quarter fiscal 2017, a 20.9% increase on a year-over-year basis.
VEEV: 40.74 (+0.51), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), LNTH: 9.40 (-0.10), NUVA: 66.74 (+0.68)
BioTelemetry Gets CE Mark for Holter Monitoring Software
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:38AM CDT
BioTelemetry (BEAT) recently announced the receipt of CE mark for its Holter analysis software.
MASI: 59.90 (+0.47), BEAT: 18.82 (+0.12), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Luminex Poised on Pipeline Strength, System Sales Upbeat
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:19AM CDT
Austin-based Luminex (LMNX) is well poised on pipeline strength and solid system sales.
MASI: 59.90 (+0.47), QDEL: 21.58 (-0.16), LMNX: 21.12 (+0.19), NUVA: 66.74 (+0.68)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.73 (+0.45), PAHC: 25.86 (+0.27), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68), HRC: 59.97 (+0.72)
Uptrend Call Working As NuVasive Stock Rises 45.1% (NUVA)
Comtex SmarTrend(R) - Fri Aug 26, 12:57PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 6 months, NuVasive has returned 45.12% as of today's recent price of $63.10.
NUVA: 66.74 (+0.68)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
PRA Health Sciences (PRAH) Hits 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:59AM CDT
Share price of PRA Health Sciences (PRAH) rallied to a new 52-week high of $52.72 on Aug 23, eventually closing a tad bit higher at $52.59.
MASI: 59.90 (+0.47), PRAH: 50.38 (-0.18), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
BioTelemetry Forms Partnership with Bloomlife, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:57AM CDT
BioTelemetry announced a strategic partnership with Bloom Technologies.
MASI: 59.90 (+0.47), BEAT: 18.82 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), HTWR: 58.20 (+0.22), NUVA: 66.74 (+0.68)
Akers Biosciences OxiCheck Study Results Positive, Stock Up
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:21AM CDT
Akers Biosciences Inc. (AKER) recently announced favorable clinical results for its BreathScan OxiCheck disposable breath test.
CAH: 79.73 (+0.03), QDEL: 21.58 (-0.16), AKER: 3.66 (+0.13), NUVA: 66.74 (+0.68)
Alere (ALR) Receives FDA Approval for RSV Molecular Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 7:16AM CDT
Alere recently announced 510(k) approval from the U.S. Food and Drug Administration (FDA) for its Alere i RSV test.
QDEL: 21.58 (-0.16), LNTH: 9.40 (-0.10), ALR: 39.13 (+0.69), NUVA: 66.74 (+0.68)
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.40 (+1.05), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Bet on These 5 Profitable Stocks for Big Returns
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 6:26AM CDT
A company with strong profit generating capabilities usually has the proficiency to meet business expenses and create steady returns for investors.
FB: 126.51 (+0.34), TPH: 13.44 (+0.07), PE: 34.86 (+0.57), CORT: 5.31 (-0.04), NUVA: 66.74 (+0.68)
NuVasive to Participate in Investor Events in September 2016
Marketwired - Fri Sep 02, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - September 02, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will participate in the following investor events in September 2016:
WFC: 50.55 (+0.12), NUVA: 66.74 (+0.68)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 40.64 (+0.93), BDX: 177.32 (+0.30), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
Inogen Hits 52-Week High on Solid Q2 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:01AM CDT
Share price of Inogen Inc (INGN) rallied to a new 52-week high of $59 on Aug 30, eventually closing a tad bit lower at $58.46.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), NUVA: 66.74 (+0.68)
Veeva Systems (VEEV) Q2 Earnings, Revenues Top; View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:57AM CDT
Veeva Systems (VEEV) reported adjusted earnings of 15 cents per share in the second-quarter fiscal 2017, a 20.9% increase on a year-over-year basis.
VEEV: 40.74 (+0.51), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), LNTH: 9.40 (-0.10), NUVA: 66.74 (+0.68)
BioTelemetry Gets CE Mark for Holter Monitoring Software
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:38AM CDT
BioTelemetry (BEAT) recently announced the receipt of CE mark for its Holter analysis software.
MASI: 59.90 (+0.47), BEAT: 18.82 (+0.12), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Luminex Poised on Pipeline Strength, System Sales Upbeat
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:19AM CDT
Austin-based Luminex (LMNX) is well poised on pipeline strength and solid system sales.
MASI: 59.90 (+0.47), QDEL: 21.58 (-0.16), LMNX: 21.12 (+0.19), NUVA: 66.74 (+0.68)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.73 (+0.45), PAHC: 25.86 (+0.27), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68), HRC: 59.97 (+0.72)
Uptrend Call Working As NuVasive Stock Rises 45.1% (NUVA)
Comtex SmarTrend(R) - Fri Aug 26, 12:57PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 6 months, NuVasive has returned 45.12% as of today's recent price of $63.10.
NUVA: 66.74 (+0.68)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), NUVA: 66.74 (+0.68)
PRA Health Sciences (PRAH) Hits 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:59AM CDT
Share price of PRA Health Sciences (PRAH) rallied to a new 52-week high of $52.72 on Aug 23, eventually closing a tad bit higher at $52.59.
MASI: 59.90 (+0.47), PRAH: 50.38 (-0.18), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
BioTelemetry Forms Partnership with Bloomlife, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:57AM CDT
BioTelemetry announced a strategic partnership with Bloom Technologies.
MASI: 59.90 (+0.47), BEAT: 18.82 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.32 (+0.34), GWPH: 82.73 (+0.45), QDEL: 21.58 (-0.16), HTWR: 58.20 (+0.22), NUVA: 66.74 (+0.68)
Akers Biosciences OxiCheck Study Results Positive, Stock Up
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:21AM CDT
Akers Biosciences Inc. (AKER) recently announced favorable clinical results for its BreathScan OxiCheck disposable breath test.
CAH: 79.73 (+0.03), QDEL: 21.58 (-0.16), AKER: 3.66 (+0.13), NUVA: 66.74 (+0.68)
Alere (ALR) Receives FDA Approval for RSV Molecular Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 7:16AM CDT
Alere recently announced 510(k) approval from the U.S. Food and Drug Administration (FDA) for its Alere i RSV test.
QDEL: 21.58 (-0.16), LNTH: 9.40 (-0.10), ALR: 39.13 (+0.69), NUVA: 66.74 (+0.68)
(0)
(0)Scroll down for more posts ▼